KRAS and lung cancer: In an oncogenic kRas-driven lung cancer mouse model, Atg5 deficiency is associated with an increase in the numbers of early hyperplastic foci and regulatory T cells, and then further antibody treatment or depletion of FoxP3+ cells decrease the hyperplastic lesions to those seen in the controls [36].